PURPOSE: Although low doses of oxygen (FiO2 <0.50) are considered nontoxic, recent studies have shown that even lower doses increase pulmonary inflammatory mediators. We aimed to evaluate the acute effects of reducing FiO2 on pulmonary inflammation in mechanically ventilated patients without respiratory failure. METHODS: This study was a prospective, single-center crossover study in a medical/surgical intensive care unit at a university hospital. Hemodynamically stable patients under mechanical ventilation for >24 h without severe respiratory failure (PaO2/FiO2 >250). A basal FiO2 of 0.40 was reduced to 0.21 provided SpO2 remained higher than 90 %. Patients who could not tolerate the reduction in FiO2 to 0.21 were excluded. RESULTS: We screened 40 patients, but only 28 (70 %) tolerated FiO2 0.21. We measured common clinical variables and inflammatory mediators in plasma and in exhaled breath condensate (EBC) at the end of three 4-h periods: (1) basal (FiO2 0.40), (2) after FiO2 reduction to 0.21, and (3) after returning FiO2 0.40. We used one-way ANOVA for repeated measurements with FiO2 as the grouping variable. Median values of inflammatory mediators in EBC showed nonsignificant changes among the three periods: NO2 + NO3 17.1, 14.1 and 11.0 μmol/L (p = 0.2), and 8-isoprostane 4.4, 8.2 and 5.3 pg/ml (p = 0.6) for the three periods, respectively. Plasma levels also showed nonsignificant changes during the period of the study: NO2 + NO3 12.6, 16.3 and 15.0 μmol/L (p = 0.9), TNFα 13.5, 18.0 and 14.5 pg/ml (p = 0.8), IL-4 12.9, 18.7 and 23.9 pg/ml (p = 0.1), IL-6 50.9, 35.1 and 28.3 pg/ml (p = 0.6), and IL-10 15.2, 22.2 and 22.2 pg/ml (p = 0.7) for the three periods, respectively. CONCLUSION:FiO2 0.40 in mechanically ventilated patients without severe respiratory failure did not increase systemic or pulmonary inflammation.
RCT Entities:
PURPOSE: Although low doses of oxygen (FiO2 <0.50) are considered nontoxic, recent studies have shown that even lower doses increase pulmonary inflammatory mediators. We aimed to evaluate the acute effects of reducing FiO2 on pulmonary inflammation in mechanically ventilated patients without respiratory failure. METHODS: This study was a prospective, single-center crossover study in a medical/surgical intensive care unit at a university hospital. Hemodynamically stable patients under mechanical ventilation for >24 h without severe respiratory failure (PaO2/FiO2 >250). A basal FiO2 of 0.40 was reduced to 0.21 provided SpO2 remained higher than 90 %. Patients who could not tolerate the reduction in FiO2 to 0.21 were excluded. RESULTS: We screened 40 patients, but only 28 (70 %) tolerated FiO2 0.21. We measured common clinical variables and inflammatory mediators in plasma and in exhaled breath condensate (EBC) at the end of three 4-h periods: (1) basal (FiO2 0.40), (2) after FiO2 reduction to 0.21, and (3) after returning FiO2 0.40. We used one-way ANOVA for repeated measurements with FiO2 as the grouping variable. Median values of inflammatory mediators in EBC showed nonsignificant changes among the three periods: NO2 + NO3 17.1, 14.1 and 11.0 μmol/L (p = 0.2), and 8-isoprostane 4.4, 8.2 and 5.3 pg/ml (p = 0.6) for the three periods, respectively. Plasma levels also showed nonsignificant changes during the period of the study: NO2 + NO3 12.6, 16.3 and 15.0 μmol/L (p = 0.9), TNFα 13.5, 18.0 and 14.5 pg/ml (p = 0.8), IL-4 12.9, 18.7 and 23.9 pg/ml (p = 0.1), IL-6 50.9, 35.1 and 28.3 pg/ml (p = 0.6), and IL-10 15.2, 22.2 and 22.2 pg/ml (p = 0.7) for the three periods, respectively. CONCLUSION:FiO2 0.40 in mechanically ventilated patients without severe respiratory failure did not increase systemic or pulmonary inflammation.
Authors: F Javier Belda; Luciano Aguilera; José García de la Asunción; Javier Alberti; Rosario Vicente; Lucía Ferrándiz; Rafael Rodríguez; Roque Company; Daniel I Sessler; Gerardo Aguilar; Stephanie García Botello; Rafael Ortí Journal: JAMA Date: 2005-10-26 Impact factor: 56.272
Authors: J Hope Kilgannon; Alan E Jones; Nathan I Shapiro; Mark G Angelos; Barry Milcarek; Krystal Hunter; Joseph E Parrillo; Stephen Trzeciak Journal: JAMA Date: 2010-06-02 Impact factor: 56.272
Authors: Christian S Meyhoff; Jørn Wetterslev; Lars N Jorgensen; Steen W Henneberg; Claus Høgdall; Lene Lundvall; Poul-Erik Svendsen; Hannah Mollerup; Troels H Lunn; Inger Simonsen; Kristian R Martinsen; Therese Pulawska; Lars Bundgaard; Lasse Bugge; Egon G Hansen; Claus Riber; Peter Gocht-Jensen; Line R Walker; Asger Bendtsen; Gun Johansson; Nina Skovgaard; Kim Heltø; Andrei Poukinski; André Korshin; Aqil Walli; Mustafa Bulut; Palle S Carlsson; Svein A Rodt; Liselotte B Lundbech; Henrik Rask; Niels Buch; Sharafaden K Perdawid; Joan Reza; Kirsten V Jensen; Charlotte G Carlsen; Frank S Jensen; Lars S Rasmussen Journal: JAMA Date: 2009-10-14 Impact factor: 56.272
Authors: G Capellier; P Beuret; G Clement; F Depardieu; C Ract; J Regnard; D Robert; F Barale Journal: Intensive Care Med Date: 1998-05 Impact factor: 17.440
Authors: Evert de Jonge; Linda Peelen; Peter J Keijzers; Hans Joore; Dylan de Lange; Peter H J van der Voort; Robert J Bosman; Ruud A L de Waal; Ronald Wesselink; Nicolette F de Keizer Journal: Crit Care Date: 2008-12-10 Impact factor: 9.097
Authors: Elie Azoulay; Giuseppe Citerio; Jan Bakker; Matteo Bassetti; Dominique Benoit; Maurizio Cecconi; J Randall Curtis; Glenn Hernandez; Margaret Herridge; Samir Jaber; Michael Joannidis; Laurent Papazian; Mark Peters; Pierre Singer; Martin Smith; Marcio Soares; Antoni Torres; Antoine Vieillard-Baron; Jean-François Timsit Journal: Intensive Care Med Date: 2014-01-24 Impact factor: 17.440
Authors: Ana Fernandez-Bustamante; Jelena Klawitter; John E Repine; Amanda Agazio; Allison J Janocha; Chirag Shah; Marc Moss; Ivor S Douglas; Zung Vu Tran; Serpil C Erzurum; Uwe Christians; Tamas Seres Journal: Anesthesiology Date: 2014-09 Impact factor: 7.892
Authors: Hendrik J F Helmerhorst; Laura R A Schouten; Gerry T M Wagenaar; Nicole P Juffermans; Joris J T H Roelofs; Marcus J Schultz; Evert de Jonge; David J van Westerloo Journal: Intensive Care Med Exp Date: 2017-05-26